Frequently Asked Questions

Oculentis Medical Pvt. Ltd., Mumbai, manufactures and markets a complete ophthalmic portfolio for the Indian market — sterile eye drops across anti-infective, lubricant, anti-glaucoma, anti-allergic and NSAID therapy areas, intraocular lenses (hydrophobic and hydrophilic platforms), ophthalmic viscoelastic devices (OVDs) for cataract surgery, plus Tru Vision, an eye-nutrition nutraceutical tablet with lutein and zeaxanthin.

The portfolio includes moxifloxacin antibiotic eye drops and combinations (Moxilux, Moxilux-LP, Moxilux-D), lubricants for dry eye (Ocufina, Ocufina Gel, Restor-TF, Restor Hydra, Restor Ultra), anti-glaucoma agents (Travotis — travoprost; Brimolux T — brimonidine + timolol), the NSAID Nepalux (nepafenac), the anti-allergic Ololux (olopatadine) and Tobalux F (tobramycin + steroid). Full prescribing details are on each product page.

Yes. All Oculentis ophthalmic pharmaceutical products are licensed by CDSCO/FDA-India and manufactured and marketed in compliance with the Drugs and Cosmetics Act and Rules for the Indian market. Manufacturing licences and product permissions are available to qualified trade partners and institutional buyers on request.

Oculentis products are manufactured under WHO-GMP compliant sterile production conditions within an ISO 13485 quality management system. Every batch is released with a certificate of analysis, and batch-level traceability is maintained from raw material to dispatch.

Most Oculentis eye drops — antibiotics, steroid combinations, NSAIDs and anti-glaucoma agents — are prescription medicines and should be used only on the advice of a registered medical practitioner. Lubricant drops and the Tru Vision eye-nutrition supplement are positioned for professional recommendation as well. Always follow the prescribing information supplied with the product.

Moxilux (moxifloxacin 0.5%) is our broad-spectrum fluoroquinolone for bacterial conjunctivitis and ocular infections. Moxilux-LP (moxifloxacin + loteprednol) and Moxilux-D (moxifloxacin + dexamethasone) combine the antibiotic with a steroid where inflammation accompanies infection, and Tobalux F pairs tobramycin with a steroid. Choice of agent rests with the treating ophthalmologist.

Our lubricant range covers mild to severe dry eye: Ocufina and the Restor family (Restor-TF, Restor Hydra, Restor Ultra) for daily lubrication, and Ocufina Gel for longer-lasting relief, including overnight use. These are among the most frequently recommended lubricating eye drops for screen-related and age-related dry eye in India.

Travotis (travoprost 0.004%) is a once-daily prostaglandin analogue for open-angle glaucoma and ocular hypertension, and Brimolux T (brimonidine 0.2% + timolol 0.5%) is a fixed-dose combination for patients needing dual-mechanism IOP control. Anti-glaucoma therapy must be initiated and monitored by an ophthalmologist.

Ololux (olopatadine) is our anti-allergic for itching, redness and watering due to allergic conjunctivitis. Nepalux (nepafenac) is a topical NSAID used for pain and inflammation, including post-operative ocular inflammation as directed by the surgeon.

Tru Vision is Oculentis Medical's eye-nutrition nutraceutical — a tablet formulated with lutein and zeaxanthin, macular carotenoids that support retinal health. It is positioned as daily nutritional support for eye health and is marketed in India as a nutraceutical, not as a treatment for any disease.

Hospitals, eye clinics and institutional buyers across India can order directly through our sales team or via our authorised distribution network. Write to sales@oculentismedical.com or use the Contact page with your product list and quantities; procurement documentation including licences, CoAs and price lists is provided for hospital pharmacy and tender files.

MOQs vary by product and pack size, with flexible quantities for hospital evaluation orders and new accounts. Share your product list and expected monthly volumes through the Contact page and our team will revert with a tailored quotation and supply terms for your institution or territory.

Yes. Verified healthcare professionals at Indian hospitals and eye clinics can request evaluation samples of any Oculentis eye drop through the Request a Sample page. Samples are supplied for professional evaluation at no product cost, typically delivered within 5–10 business days across India after confirmation.

Yes. Oculentis supports institutional and tender supply within India with the required regulatory and quality documentation — manufacturing licences, WHO-GMP and ISO certificates, and batch certificates of analysis. Contact our institutional sales team with your tender schedule and specifications.

Pharmaceutical distributors, stockists and PCD/franchise partners anywhere in India can apply through the Become a Distributor page. We evaluate applicants on their pharma distribution licences, ophthalmic or pharma sales network, storage capability and territory coverage. Selected partners receive product training, promotional inputs and documentation support.

We appoint partners state-wise across India, and territory availability is confirmed during qualification. Exclusive or monopoly arrangements for defined districts or states are discussed on merit and agreed in writing — we do not promise exclusivity before qualification.

No. Oculentis Medical serves the Indian market only. All manufacturing, licensing and distribution activities are focused on India, and we do not currently accept export or international supply enquiries.

Oculentis Medical Pvt. Ltd. is headquartered at 501-A, Pinnacle Corporate Park, 5th Floor, Near Trade Center, Bandra Kurla Complex (BKC), Bandra (E), Mumbai 400051, Maharashtra, India.

Store as directed on the product label — typically below 25°C or 30°C, protected from light, and never frozen. Do not use beyond the expiry date, and discard multi-dose bottles within the period stated in the pack insert after first opening (commonly 28 days for preserved eye drops). Keep out of reach of children.

Adverse events, product complaints or suspected quality issues involving any Oculentis product should be reported immediately to our pharmacovigilance team at pv@oculentismedical.com or via the online Report an Adverse Event form. Reports are handled confidentially under our pharmacovigilance procedures and shared with regulatory authorities in India as required by law. Please include the batch number and do not include patient-identifying details.